Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)

被引：1

作者：

Sugarman, Ryan

Nunna, Sasikiran

Betts, Keith A.

Nie, Xiaoyu

Nguyen, Hiep

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Bristol Myers Squibb, Lawrenceville, NJ USA

[3] Anal Grp Inc, Los Angeles, CA USA

[4] Bristol Myers Squibb Co, Lawrenceville, NJ USA

来源：

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

307

引用

页数：3